Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Mai 2020 06:45 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics Announces Veteran Finance Executive Stephen Webster Joins its Board of Directors

CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients...
15. April 2020 06:45 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics Announces Immuno-Oncology Pioneer Dr. Axel Hoos Joins its Board of Directors

CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
03. April 2020 07:00 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics to Present at the Goldman Sachs Cell Therapy Day

CAMBRIDGE, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
30. März 2020 06:45 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Company initiated Phase 1/2 clinical trial for TC-110, its lead hematological malignancy candidateInterim update from Phase 1 portion of TC-210 Phase 1/2 trial anticipated in 2Q20 and Phase 1/2 trial...
18. Februar 2020 07:00 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics to Participate in Two Upcoming Conferences in February

CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
03. Februar 2020 08:00 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics to Present an Allogeneic Construct at the Keystone Symposia Conference on Emerging Cellular Therapies: Cancer and Beyond

CAMBRIDGE, Mass., Feb. 03, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
07. Januar 2020 07:00 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
12. November 2019 07:00 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
09. Oktober 2019 06:30 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics Appoints Industry Veteran Angela Justice, Ph.D., as Chief People Officer

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
27. September 2019 08:00 ET | Quelle: TCR2 Therapeutics

TCR² Therapeutics to Present at the Cantor Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...

Vorherige Seite

Nächste Seite